Appendix E.
Proportion of patients achieving ASAS responses (20% and 40%) with CT-P13 (5 mg/kg) or INX (5 mg/kg) at week 14 and week 30 in the all randomised population (CT-P13: N=125; INX: N=125).

Figure S2-1. ASAS20 rates at weeks 14 and 30

Response rate (%)

Week 14      Week 30
CT-P13 (5 mg/kg)  INX (5 mg/kg)
62.6 (72/115)    64.8 (79/122)  70.5 (79/112)    72.4 (84/116)

Figure S2-2. ASAS40 rates at weeks 14 and 30

Response rate (%)

Week 14      Week 30
CT-P13 (5 mg/kg)  INX (5 mg/kg)
41.7 (48/115)    45.9 (56/122)  51.8 (58/112)    47.4 (55/116)